Clinical Trial Update: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) [Phase 2]

View source ↗

Summary

Open-label Phase 2 feasibility/pilot study using the radiotracer [123I]-IBZM with SPECT imaging (DOPA-SYN) in Parkinson's disease that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• [123I]-IBZM (Iodine-123 labeled IBZM radioligand (benzodiazepine receptor ligand))

Snippet

Sponsor: Molecular NeuroImaging | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED